Kopran Limited (KOPRAN.NS)
- Previous Close
266.25 - Open
262.00 - Bid --
- Ask --
- Day's Range
255.00 - 262.00 - 52 Week Range
140.00 - 292.30 - Volume
276,260 - Avg. Volume
544,508 - Market Cap (intraday)
12.404B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
30.75 - EPS (TTM)
8.36 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield 3.00 (1.13%)
- Ex-Dividend Date Sep 7, 2023
- 1y Target Est
--
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as topical preparations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is headquartered in Mumbai, India.
www.kopran.com902
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: KOPRAN.NS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KOPRAN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KOPRAN.NS
Valuation Measures
Market Cap
12.85B
Enterprise Value
13.70B
Trailing P/E
31.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.23
Price/Book (mrq)
2.91
Enterprise Value/Revenue
2.38
Enterprise Value/EBITDA
19.02
Financial Highlights
Profitability and Income Statement
Profit Margin
6.97%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.79B
Net Income Avi to Common (ttm)
403.74M
Diluted EPS (ttm)
8.36
Balance Sheet and Cash Flow
Total Cash (mrq)
74.49M
Total Debt/Equity (mrq)
21.11%
Levered Free Cash Flow (ttm)
--